Furthermore, BRCA2 PTVs were associated with a high risk of breast cancer overall, ER-positive and triple-negative disease and exceeded the 80-year cumulative risk threshold for high risk (30%), as defined by the NICE surveillance screening guidelines ((NICE) 2019). This evidence concerns the gene ESR1 and breast carcinoma.